Elanco Animal Health [ELAN] vs Intra-Cellular [ITCI] Detailed Stock Comparison

Elanco Animal Health Inc.

NYSE
Loading...

Intra-Cellular Therapies Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Elanco Animal Health Inc. wins in 14 metrics, Intra-Cellular Therapies Inc. wins in 4 metrics, with 0 ties. Elanco Animal Health Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Elanco Animal Health Inc. Intra-Cellular Therapies Inc. Better
P/E Ratio (TTM) 377.14 -183.15 Elanco Animal Health Inc.
Price-to-Book Ratio 1.72 12.20 Elanco Animal Health Inc.
Debt-to-Equity Ratio 67.89 1.48 Intra-Cellular Therapies Inc.
PEG Ratio 0.14 507.19 Elanco Animal Health Inc.
EV/EBITDA 16.68 -112.19 Elanco Animal Health Inc.
Profit Margin (TTM) -4.92% -10.97% Elanco Animal Health Inc.
Operating Margin (TTM) 2.27% -14.66% Elanco Animal Health Inc.
EBITDA Margin (TTM) 2.27% N/A N/A
Return on Equity -3.67% -8.58% Elanco Animal Health Inc.
Return on Assets (TTM) 1.25% -6.96% Elanco Animal Health Inc.
Free Cash Flow (TTM) $284.00M $-73.50M Elanco Animal Health Inc.
1-Year Return 75.02% 92.68% Intra-Cellular Therapies Inc.
Price-to-Sales Ratio (TTM) 2.39 20.63 Elanco Animal Health Inc.
Enterprise Value $15.14B $13.04B Elanco Animal Health Inc.
EV/Revenue Ratio 3.21 19.15 Elanco Animal Health Inc.
Gross Profit Margin (TTM) 51.49% 89.76% Intra-Cellular Therapies Inc.
Revenue per Share (TTM) $10 $7 Elanco Animal Health Inc.
Earnings per Share (Diluted) $-0.47 $-0.73 Elanco Animal Health Inc.
Beta (Stock Volatility) 1.88 0.46 Intra-Cellular Therapies Inc.
Short % of Float 8.13% N/A N/A

Elanco Animal Health Inc. vs Intra-Cellular Therapies Inc. Stock Performance Analysis

Loading Price Chart...

ELAN
ITCI

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Elanco Animal Health Inc.0.50%2.58%22.31%3.80%11.94%7.86%
Intra-Cellular Therapies Inc.0.00%N/AN/AN/AN/AN/A

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Elanco Animal Health Inc.75.02%133.08%-30.33%-29.12%-29.12%-29.12%
Intra-Cellular Therapies Inc.92.68%104.13%700.67%449.92%632.61%632.61%

Performance & Financial Health Analysis: Elanco Animal Health Inc. vs Intra-Cellular Therapies Inc.

MetricELANITCI
Market Information
Market Cap i$11.18B$14.05B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i4,096,5392,749,368
90 Day Avg. Volume i5,352,8902,309,509
Last Close$24.29$131.87
52 Week Range$13.16 - $27.72$64.09 - $131.98
% from 52W High-12.37%-0.08%
All-Time High$37.61 (Sep 24, 2018)$131.98 (Mar 31, 2025)
% from All-Time High-35.42%-0.08%
Growth Metrics
Quarterly Revenue Growth0.12%0.51%
Quarterly Earnings Growth0.12%0.51%
Financial Health
Profit Margin (TTM) i-0.05%-0.11%
Operating Margin (TTM) i0.02%-0.15%
Return on Equity (TTM) i-0.04%-0.09%
Debt to Equity (MRQ) i67.891.48
Cash & Liquidity
Book Value per Share (MRQ)$13.17$10.81
Cash per Share (MRQ)$1.10$9.42
Operating Cash Flow (TTM) i$560.00M$-73,177,000
Levered Free Cash Flow (TTM) i$559.75M$-63,549,624
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Elanco Animal Health Inc. vs Intra-Cellular Therapies Inc.

MetricELAN (Apr 23, 2026)ITCI (May 17, 2025)
Price Ratios
P/E Ratio (TTM) i377.14-183.15
Forward P/E i19.35507.19
PEG Ratio i0.14507.19
Price to Sales (TTM) i2.3920.63
Price to Book (MRQ) i1.7212.20
Market Capitalization
Market Capitalization i$11.18B$14.05B
Enterprise Value i$15.14B$13.04B
Enterprise Value Metrics
Enterprise to Revenue i3.2119.15
Enterprise to EBITDA i16.68-112.19
Risk & Other Metrics
Beta i1.880.46
Book Value per Share (MRQ) i$13.17$10.81

Financial Statements Comparison: Elanco Animal Health Inc. vs Intra-Cellular Therapies Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricELAN (2025)ITCI (2024)
Revenue/Sales i4.72B680.50M
Cost of Goods Sold i2.12B56.96M
COGS % of Revenue i45.0%8.4%
Gross Profit i2.59B623.54M
Gross Margin i55.0%91.6%
Research & Development i368.00M236.12M
Operating Income (EBIT) i252.00M-116.72M
Operating Margin i5.3%-17.2%
EBITDA i913.00M-116.21M
EBITDA Margin i19.4%-17.1%
Pre-Tax Income i-224.00M-74.20M
Pre-Tax Income % of Revenue i-4.8%-10.9%
Income Tax i8.00M473,000
Income Tax % of Revenue i0.2%0.1%
Net Income (Profit) i-232.00M-74.68M
Profit Margin i-4.9%-11.0%

Balance Sheet & Liquidity Metrics

MetricELAN (2025)ITCI (2024)
Cash & Equivalents i545.00M306.95M
Total Current Assets i3.46B1.31B
Total Current Assets % of Revenue i73.3%192.1%
Total Current Liabilities i1.60B205.70M
Total Current Liabilities % of Revenue i33.9%30.2%
Long-Term Debt i3.94B12.75M
Long-Term Debt % of Revenue i83.6%1.9%
Total Shareholders Equity i6.55B1.15B
Retained Earnings i-2.18B-1.69B
Retained Earnings % of Revenue i-46.3%-248.6%
Property, Plant & Equipment i1.33B14.90M

Cash Flow Statement Comparison

MetricELAN (2025)ITCI (2024)
Operating Cash Flow i489.00M-63.27M
Operating Cash Flow % of Revenue i10.4%-9.3%
Capital Expenditures i-276.00M-322,000
Free Cash Flow i284.00M-73.50M
FCF Margin i6.0%-10.8%
Debt Repayment i-2.92BN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricELANITCI
Shares Short i25.54MN/A
Short Ratio i4.53N/A
Short % of Float i8.13%N/A
Shares Outstanding i496.98M106.24M
Float Shares i492.68M104.82M
% Held by Insiders i1.19%2.48%
% Held by Institutions i109.45%96.45%
% Held by Public i-10.64%1.07%

Dividend Analysis & Yield Comparison: Elanco Animal Health Inc. vs Intra-Cellular Therapies Inc.

MetricELANITCI
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A